ArticleBMC public health2026
Forecasting monthly hepatitis B cases in China: a nationwide comparative study based on surveillance data.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRobust forecasting of hepatitis B trends is important for long-term surveillance and public health planning in China. However, evidence remains limited regarding how different forecasting frameworks perform when applied to a long-term national hepatitis B surveillance series under a unified out-of-sample evaluation design.
methodsMonthly reported hepatitis B cases in China from January 2004 to December 2024 were obtained from national public surveillance databases. Data from January 2004 to December 2023 were used as the training set, whereas data from January to December 2024 were reserved as an independent validation set. Ten forecasting models were evaluated, including Seasonal autoregressive integrated moving average (SARIMA), Bayesian structural time series (BSTS), four standalone machine-learning models (random forest, support vector machine, XGBoost, and LightGBM), and four residual-based SARIMA-machine-learning hybrid models. Model performance was assessed using mean absolute error (MAE), range-normalized root mean square error (NRMSE), mean absolute percentage error (MAPE) and Nash-Sutcliffe Efficiency (NSE). In addition, the average annual percentage change (AAPC) was estimated to summarize the long-term annual trend in reported case counts.The best-performing models were further used to forecast monthly hepatitis B case counts in 2025.
resultsA total of 252 monthly observations were included. The mean monthly number of reported hepatitis B cases was 91,901. The annual reported case counts did not show a statistically significant long-term trend (AAPC = - 0.561%, P = 0.12), whereas the monthly series exhibited a stable seasonal pattern, with peaks typically occurring in March and troughs in December followed by January. Among the candidate SARIMA structures, SARIMA(2, 1, 0)(1, 0, 3)
conclusionsForecasting performance differed across model classes in long-term national hepatitis B surveillance. BSTS showed the best overall predictive performance. These findings support empirical model selection and suggest that BSTS-based forecasting may serve as a supportive tool for early warning, resource allocation, and long-term hepatitis B surveillance planning when interpreted together with reporting-system and policy context.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.